Transforming Alzheimer's Screening

ALZAI is the first AI-driven Alzheimer’s Disease risk screening platform using non-invasive, low-cost, pre-existing biomarker data, providing early detection and improving patient outcomes.

Risk Assessment & Early Detection

Identifies Alzheimer’s disease risk up to 10 years before symptoms appear, enabling earlier intervention and better patient outcomes.

Proven Results with over 500,000 patients

Proven effectiveness with over 500,000 diverse patients, demonstrating unparalleled and reliable screening capabilities.

Accessible for everyone, everywhere

Delivering Non-Invasive, low-cost screening solution enabling Alzheimer’s screening for entire patient populations.

Seamless Screening Experience

Built on a use -friendly, easily integrated platform for healthcare providers, clinical researchers, and stakeholders to engage ALZAI Screening.

Our Mission

Our mission is quite simple, to address a major unmet need in Alzheimer’s - Screening. Screening for disease risk enables early detection and mitigation driving the right people to diagnosis, therapy or prevention.

Our Vision

In a perfect world, everyone over 50 would be screened for Alzheimers Disease. ALZAI can assess risk of developing disease, ushering in the pre-Alzheimers & designation, enabling preventative care. ALZAI would also detect for more early stage disease, enabling more people to be diagnosed early, enabling earlier intervention - when therapies work best.

80%+

Sensitivity detecting who will be diagnosed with Alzheimer’s.

10 years

Screening for disease risk up to 10 years out.

400%

More sensitive than existing screening methods.

30+

Biomarkers used, present in common medical records.

500,000+

Real world patient medical records trained with AI.

OUR TEAM

Founding Management Team

Hayim Raclaw

Director, CEO & Co-founder

  • Experienced multi-time founder & executive leader.
  • 25 years experience in medical technologies including imaging, surgical technologies, disease diagnostics, mental health clinics, and venture capital.
  • Track record of value-creation for stakeholders.
Roy Kait

Director, CRO & Co-founder

  • 15+ years of experience in startups, entrepreneurial ventures, corporate finance, and strategy.
  • Led M&A at IMC (NASDAQ: IMCC, CSE: IMCC) with total activity of over $180M.
  • Former Israeli Air Force Pilot (Res.)
Dr. Amir Glik, MD

Director, CMO & Co-founder

  • Senior Neurologist, Clalit Health Services Israel.
  • Head of Cognitive Neurology Service, Beilinson Hospital, Rabin Medical Center.
  • Holds patents on multiple research projects.
Dr. Chen Hajaj

Director, Data Science Lead & Co-founder

  • Founder, Data Science & Artificial Intelligence Research Center.
  • Faculty, Industrial Engineering and Management, Ariel University.
  • Recognized machine learning expert and educator.
Our ADVISORY Team

Expert Advisory Board

Dr. Michael Greenberg, M.D.

Advisor

  • Medical degree from the University of Pennsylvania.
  • Trained as a neurosurgery resident at the University of Toronto.
  • Conducted neuroscience research as a US National Institutes of Health postdoctoral fellow.
Prof. Lindsay A. Farrer, Ph.D.

Advisor

  • Leads a worldwide collaboration of laboratories researching Alzheimer’s disease.
  • Chief, Biomedical Genetics, Boston University School of Medicine.
  • Distinguished professor of genetics, medicine, neurology, ophthalmology, epidemiology, and biostatistics.
Mr. Uri Bettesh

Advisor

  • Founder & CEO of Datos Health, a leading Clinical Patient Engagement Platform.
  • 18 years of experience as a technology executive.
  • Proven track record of leading complex technologies from ideation to product.
Mr. Ken Milman

Advisor

  • Founder & CEO of Alertcloud LLC, specializing in business process automation for US healthcare.
  • 15 years of experience delivering tech solutions for Fortune 500 companies.
  • Deep understanding of tech and regulatory environments in the healthcare sector.